EDMONTON, Sept. 14 /PRNewswire-FirstCall/ - Isotechnika Inc. announced
today the participation level in its Canadian Phase III psoriasis extension
trial for its lead immunosuppressive drug, ISA247.
    Patients completing the 24 week Canadian Phase III SPIRIT trial were
given the opportunity to continue therapy for an additional 36 weeks or to
discontinue therapy. Of the patients who completed the 24 week trial 90% chose
to continue treatment. The patients who enrolled in the open label extension
trial are receiving administration of oral ISA247 capsules at 0.3 mg/kg twice
daily, which was the mid-dose used in the SPIRIT trial. The goals of the
extension trial are to provide continued therapeutic benefit to psoriasis
patients and to gather longer term safety and efficacy data. This data should
facilitate the advancement of ISA247 through the clinical trial process.
    "As a clinical investigator with 20 years experience, the 90% enrollment
in the current Isotechnika Phase III extension trial for psoriasis speaks
volumes. It indicates patients are extremely satisfied and pleased with not
only the efficacy, but the safety of this drug. Typically, extension studies
do not normally attain such high enrollment figures," commented Dr. Charles
Lynde, a principal investigator involved in the Phase III psoriasis trial.
    "The overwhelming participation in this extension trial attests to the
high degree of acceptance of ISA247 by both the patients and the physicians,"
stated Dr. Randall Yatscoff, Isotechnika's President & COO. "We are confident
that the unblinded 12 week data from the SPIRIT trial will continue to
demonstrate a promising safety and efficacy profile for ISA247. The 12 week
unblinded results are expected to be announced in the next few weeks."

    Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. To find out
more about Isotechnika Inc. (TSX: ISA), please visit our Web site at
http://www.isotechnika.com.

    Forward-Looking Statements
    --------------------------

    This press release may contain forward-looking statements. Forward-
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward-
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements.

Link to this page: